Cardiogen

The Heart Strengthener

Strengthen Heart Muscle: Enhance Cardiac Performance with Cardiogen

Cardiogen, is a bioregulator peptide derived from peptides that are naturally occurring short chains of amino acids, extracted from animal tissues. In the case of Cardiogen, the peptides are sourced from the heart tissue of cattle. These bioregulators are designed to target specific bodily functions, with Cardiogen specifically aimed at supporting heart health. It is used with the intention of maintaining cardiovascular health, possibly aiding in the recovery of heart muscle function after cardiovascular diseases, and supporting overall cardiac performance. 

Potential Benefits Under Research

• Regulation of cardiac rhythm: Cardiogen peptides may help regulate the electrical activity of the heart, potentially aiding in the management of arrhythmias.
• Cardiac muscle repair: They could stimulate the repair and regeneration of damaged cardiac muscle tissue, potentially improving heart function after injury or disease.
• Enhancement of cardiac function: By promoting proper functioning of the heart muscle cells, cardiogen peptides may contribute to overall cardiac performance and efficiency.
• Regulation of prostate function: Cardiogen peptides may help regulate the function of the prostate gland, potentially supporting its normal physiological processes.
• Reduction of inflammation: Similar to its effects on cardiac tissue, cardiogen peptides may possess anti-inflammatory properties that could help reduce inflammation in the prostate gland, potentially lowering the risk of prostatitis or other inflammatory conditions.
• Anticancer effects: Some research suggests that cardiogen peptides may have anticancer properties, which could inhibit the growth and spread of cancer cells in various types of cancer.

Overview

Cardiogen is a short peptide with known properties as a bioregulator. Research shows that its primary effects are on fibroblasts, the cells responsible for tissue repair and scar formation throughout the body. Though the focus on cardiogen has been on its role in a variety of cardiovascular diseases (hence the name), research shows that its ability to alter fibroblast activity has potential benefits in a variety of tissues. In addition, cardiogen appears to by a synergistic peptide, enhancing the benefit of certain standard therapies and thereby improving long-term outcomes while reducing side effects. Finally, preliminary research in rat models suggests that cardiogen may increase rates of apoptosis in tumor cells. 

Structure

Molecular Formula: C1 8H31 N109
Molecular Weight: 489.5 g/mol
PubChem CID: 11583989
Alternative Names: SCHEMBL3194515

Source: PubChem 

Cardiogen and the Heart

In the heart, cardiogen appears to stimulate cardiomyocyte proliferation while reducing fibroblast growth and development. This leads to decreased scar formation and improved long-term outcomes in regards to cardiac remodeling leading to heart failure. Additionally, it appears that cardiogen 20mg can decrease p53 protein expression and thereby diminish rates of apoptosis. 

Cardiogen and Cancer 

Even though cardiogen reduces apoptosis in heart cells by down-regulating p53 expression, it may have the opposite effect in tumor cells. Research in rat models of M-1 sarcoma shows that apoptosis levels are higher in the tumor cells following cardiogen administration. What is more, the effect is dose-dependent, indicating that the biological effect is real. The peptide appears to enhance apoptosis in tumor cells and may be somewhat selective for tumor cells due to their enhanced and unusual vascular supply. This may make cardiogen a targeted treatment for at least some types of cancer. In addition, if the peptide enhances the action of standard cancer treatments (as it does in heart disease treatment), then it may prove a very potent addition to the arsenal of cancer fighters. 

Doctors Levdik and Knyazkin, both of whom have worked in some capacity with Vladimir Khavinson through the St. Petersburg Institute of Bioregulation and Gerontology and the Russian Academy of Medical Sciences, have extensive experience researching the impact of amino acids and short peptides on both cancer and healthy tissues as they become dysfunctional and precancerous. Their work with Cardiogen 20mg has positioned it as the next possible candidate for approval, in Russia, for the treatment of sarcoma. 

Cardiogen and the Prostate 

Research in tissue cultures shows that cardiogen, along with several similar peptides, alters the expression of signaling factors in fibroblasts of the prostate. Levels of these signaling factors are important in establishing favorable a microenvironment within tumors and may contribute to both the development and progression of prostate cancer. Solid evidence shows that the synthesis of these markers is substantially altered in aging and senescent fibroblasts, which may explain why prostate cancer is almost ubiquitous in older men but nearly unheard of in younger men. In fact, studies show that cardiogen can normalize levels of these signaling molecules to match or even improve upon what is seen in young cell cultures, suggesting that cardiogen may be effective both in preventing prostate cancer and in controlling its progression once it develops. 

Cardiogen Summary 

Cardiogen 20mg, while less researched than some other bioregulators, appears to have potent effects on multiple body tissues including the heart and prostate. Additionally, the peptide may be beneficial in the treatment of certain types of cancer, particularly sarcoma. Currently, the biggest benefits of cardiogen appear to be in the settings of heart attack, hypertension, and chronic heart failure where the peptide not only offers benefits of its own accord, but acts in a synergistic manner with established treatments. 

Cardiogen exhibits minimal side effects, good oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. 

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology. 

Scientific Journal Author 

Vladimir Khavinson is a Professor, resident of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice ­president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year­long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of aging and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty
“Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries. 

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Cardiogen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Guide to Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

Referenced Citations 

1. N. I. Chalisova et al., “[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats],” Adv. Gerontol. Us12..ekhi Gerontol., vol. 22, no. 3, Qp. 409-413, 2009. 
2. N. V. Levdik and I. V. Knyazkin, “Tumor­modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats,” Bull. Exp. Biol. Med., vol. 148, no. 3, Qp. 433-436, SeR.:, 2009, doi: 10.1007/s10517-010-0730-9. 
3. L. Begley, C. Monteleon, R. B. Shah, J. W. Macdonald, and J. A. Macoska, “CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro,” Aging Cell, vol. 4, no. 6, pp. 291-298, Dec. 2005, doi: 10.1111/j.1474-9726.2005.00173.x. 
4. 0. V. KheTfets, V. 0. Poliakova, and I. M. Kvetnoi, “[Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging],” Adv. Gerontol. Us12ekhi Gerontol., vol. 23, no. 1, RR- 68-70, 2010.